The creation of a global leader in Biogenerics

Alvotech was founded in 2013 by the Chairman and CEO, Robert Wessman. His initial strategy was to invest in the development and manufacture of a portfolio of biosimilar monoclonal antibodies and to build a state-of-the-art manufacturing facility in Reykjavik Iceland.

Since then, the investment commitment has increased to more than $500 million and Alvotech has established itself as a key player and up-and-coming powerhouse in the biosimilar space.

Our milestones

2013

  • Founding of Alvotech and start of development for the first two biosimilars
  • Breaking ground on state-of-the-art, 13,278 squaremeters single use biomanufacturing facility in Reykjavik, Iceland
  • Strategic investments to increase R&D capabilities

2014

  • Development of next two product candidates initiated, bringing pipeline to four biosimilars
  • Partnership agreement with a global pharma company signed

2015

  • Continuing product development and facility establishment build-up of capacity and staff

2016

  • Next two biosimilars selected to bring pipeline to six assets
  • Acquisition of development arm of Baliopharm GmbH to further strengthen our R&D platform
  • Manufacturing facility undergoing first inspection
  • Inauguration of our Icelandic facility

2017

  • One biosimilar selection to bring pipeline to seven assets
  • Acquisition of Glycothera in Hanover, Germany adding further analytical capabilities and expertise

2018

  • Manufacturing licensure granted by the Icelandic Medicines Agency, in consultation with the Irish Health Products Regulatory Authority for our biopharmaceutical facility in Reykjavik, Iceland
  • Agreement with Changchun High & New Technology Industries Group Inc (“CCHN”) which will enable Alvotech to develop, manufacture and commercialize its biosimilar portfolio in China
We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.